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Abstract 
Inflammation in the pathogenesis of cardiovascular diseases. Inflammation is the cornerstone 
of CVD. Systemic inflammation can lead to activation of the endothelium characterized by 
increased expression of endothelial adhesion molecules and chemokines (e.g., vascular adhesion 
molecules [VCAM] and monocyte chemotactic protein [MCP-1]), as well as reduced expression 
of anti-atherogenic molecules. Statins are the most effective treatment for hyperlipidemia and 
remain the gold standard for the treatment of vascular inflammation and CVD.  
New strategies and approaches to targeted delivery of drugs. These approaches are mainly 
based on two main aspects: 1) pharmaceutical composition which allows to encapsulate 
therapeutic agents; 2) surface functionalization with the help of a target agent (i.e., antibodies and 
small molecules) for drug delivery to endothelium. Nanostructured mesoporous silicon vectors 
(MSV) charged with 10-nm polymer micelles are used as a tool for the treatment of chronic heart 
failure. Another approach is the development of carriers that are analogues of natural adhesion 
molecules (CAM) or selectin ligands.  
The strategy of treatment of cardiovascular diseases with preparations based on 
nanoparticles. For the visualization of atherosclerotic plaques, nanoparticles conjugated with 
indium (111In) based on antibodies bound to LOX-1 receptors of low density were used in mice. 
New ideas and opportunities for drug development.  1) development of carrier-based 
microorganisms (such as bacteria or viruses), or cells (e.g. leukocytes, erythrocytes, platelets and 
stem cells); 2) development of nanoparticles with analogues of biologically active molecules that 
bind to cell membranes. Additional approaches include lacto-glycolic acid polymers (PLGA). 
Another approach to delivering drugs to the endothelium is to create a nanocapsule based on high 
molecular weight polymers with a nucleus containing a drug substance. This may allow switching 
from a three-compartment pharmacokinetic model to a one-cell model. 
Key words: inflammation of blood vessels; nanoparticulate drug delivery systems; C- reactive 
protein; NF-kB; endothelium. 
Introduction. 
Currently, cardiovascular diseases (CVD) are 
the leading cause of urgent hospitalization and the 
leading cause of death in many industrialized 
countries. A single point of view on the causes of 
these diseases at the moment, not fully formulated, 
but experimental and clinical studies indicate a 
pivotal role of endothelial dysfunction in their 
pathogenesis [1, 2]. 
Cardiovascular diseases are multifactorial 
complex pathologies, which is usually associated 
with hypercholesterolemia, diabetes, smoking, 
hypertension and aging. It is known that each of these 
states contributes to damage of the vascular 
endothelium and the development of pathology. It 
should be noted that the presence of overweight 
contributes to the development of metabolic 
syndrome, inflammation of blood vessels and 
Rus. 
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progression of atherosclerosis. For example, nearly 
one-third of American children are overweight or 
obese, which contributes to the initiation they have 
vascular lesions. In patients with obesity, the number 
of macrophages, free fatty acids (FFA) and 
proinflammatory mediators (e.g., tumor necrosis 
factor-α (TNF – α), interleukin 6 (IL-6), C-reactive 
protein (CRP) and leptin) increases proportionally 
with increasing amount of visceral fat, whereas anti-
inflammatory factors (adiponectin) have an inverse 
relationship. Free fatty acids activate a nuclear 
enhancement factor of Kappa-light chain of activated 
b cells (kappa B), which leads to the development of 
TNF-α. In turn, activates lipolysis, TNF – α, which 
increases the recruitment of macrophages and 
induced the synthesis of IL-6, which stimulates the 
production and secretion of CRP. The interaction 
between macrophages and adipocytes significantly 
increases hepatic production of CRP and may 
increase its level, which is one of the key risk factors 
for cardiovascular disease [2, 3, 4, 5, 6, 7, 8]. 
Inflammation in the pathogenesis of 
cardiovascular diseases. 
Inflammation is the cornerstone of CVD. 
Chronic inflammation may contribute to the 
development of coronary atherosclerosis. The link 
between inflammation and coronary events, most 
likely related to the exacerbation of local 
inflammatory process in coronary plaques. Systemic 
inflammation can lead to activation of the 
endothelium characterized by increased expression of 
endothelial adhesion molecules and chemokines (e.g., 
vascular adhesion molecules [VCAM] and monocyte 
chemotactic protein [MCP-1]), as well as reduced 
expression of anti-atherogenic molecules (nitric 
oxide and prostacyclin). Systemic inflammation 
alters the blood clotting mechanism and increase 
platelet activation, creating a procoagulant state. 
Endothelial activation due to systemic inflammation 
may be a symptom of end-stage cardiovascular 
diseases such as congestive heart failure with 
elevated levels of circulating inflammatory cytokines 
(TNF-α, IL-6, CRP) [9, 10, 11, 12, 13, 14]. 
Proinflammatory cytokines reduce the 
concentration of lipoprotein cholesterol low-density 
particles (LCNP) and increase the concentration of 
triglycerides, which in turn increases the adverse lipid 
profile associated with cardiovascular events. In 
addition, it is believed that LHCP becomes more 
atherogenic by oxidation, and when it is stored in the 
subendothelial space. In the wall of the inflamed vessel, 
there is increased generation of reactive oxygen species 
(ROS), which penetrate into immune cells and activate 
vascular cells. Accumulated oxidized LHCP absorbed 
by the resident macrophages, stimulating the immune 
cells with the formation of inflammatory cytokines and 
chemokines. Set a positive feedback loop and increases 
the expression of adhesion molecules on endothelium to 
facilitate adhesion of monocytes. The endothelium is 
particularly vulnerable to this process in areas of low 
shear stress such as bends or bifurcations or 
downstream of stenoses. Thus, the beginning and the 
spread of atherosclerosis depends on activation of the 
endothelium and vascular inflammation, which lead to 
the initiation of atherogenesis, the progression of the 
formation and rupture of plaques and thrombosis [15, 
16, 17, 18, 19, 20]. 
For the treatment of LDL the most effective and 
widely used group of drugs are the statins. Numerous 
clinical trials have proven the benefits of statins and 
their effect on LDL. Statins possess significant anti-
inflammatory effects that may inhibit kappa B 
activity by reducing the activation of genes 
regulating adhesion of endothelial permeability and 
prothrombin response. Statins also reduce the level of 
C-reactive protein in the blood, reducing the risk 
factor of cardiovascular diseases [11, 21]. 
Along with statins there are other classes of 
drugs. Quite common fibrates, angiotensin 
converting enzyme inhibitors (IAF), receptor 
blockers angiotensin, aspirin, also in the literature 
there are data on the use of L-arginine, resveratrol 
and losartan potassium. Fibrates facilitate the reverse 
transfer of cholesterol, inhibit the expression of TNF-
α and inhibit the activation of kappa B. Antiplatelet 
effects of aspirin are mainly beneficial for the 
cardiovascular system, but also prevent the 
development of proinflammatory and vasoconstrictor 
products of cyclooxygenase I (COX-1). The 
beneficial effects of angiotensin-converting enzyme 
inhibitor is due to inhibition of the formation and 
retention of angiotensin II and bradykinin, which 
increase vasodilation, the IAF exhibit anti-
inflammatory effects. For example, angiotensin II 
stimulates the infiltration and proliferation of 
monocytes and is a potent activator of NADPH 
oxidase in the vascular wall. This enzyme system is 
one of the main causes of generation of reactive 
oxygen species that oxidize LDL and inhibit nitric 
oxide, thereby cancelling the effect of this vasodilator 
endothelial factor [22, 23, 24, 25]. 
The study of anti-inflammatory therapy for the 
treatment of cardiovascular diseases is a promising 
area for the treatment of cardiovascular diseases. The 
development of approaches for delivery of drug in 
the bloodstream in order to avoid systemic side 
effects is the preferred choice when studying the 
treatment of vascular diseases. 
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New strategies and approaches to targeted 
delivery of drugs. 
Currently there are many drugs effective for the 
treatment of cardiovascular diseases. The use of new 
biologically active agents in the therapy of these 
diseases remains difficult due to their low stability in 
systemic administration and absence of effective 
methods of delivery to the affected area. In the 
modern realities are being developed for the creation 
of specialized vectors that facilitate the delivery of 
biological preparations to the most effective 
molecular targets in a desired tissue. The result was 
formed a few approaches to drug delivery in different 
sizes, classified by form and content. These 
approaches are mainly based on two main aspects:  
1) pharmaceutical composition which allows to
encapsulate in itself, therapeutic agents; 
2) functionalization surface using a targeted
agent (i.e., antibodies, aptamers and small molecules) 
for drug delivery to endothelium [26, 27]. 
For delivery of medicinal substances vascular 
system is a natural way of delivery to the lesion. 
However, the vasculature has a major drawback 
because the therapeutic agents cannot be delivered to 
a localized area due to system distribution. Recently, 
the endothelial layer was identified as a potential 
target for pharmaceutical intervention because of its 
active participation in the pathogenesis of 
cardiovascular diseases. Vascular inflammation and 
increased permeability of the endothelium is a 
common mechanism involved in the development of 
atherosclerosis, heart failure, diabetic vascular 
disease, trauma and ischemia-reperfusion. These 
endothelial changes could facilitate the delivery into 
the tissues with the help of special agents focused on 
tokens allocated to the damaged site. For example, 
nanostructured mesoporous silicon vectors (MV), in 
the form of 10-nm polymeric micelles have been 
used for the treatment of chronic heart failure. A 
team of researchers in their works have shown that 
DCA is accumulated in myocardium after 
intravenous administration, indicating improved 
cardiac permeability and retention effect. Thus, 
contrast agents, nanosensors or therapeutic agents 
can be selectively delivered to the myocardium in 
prophylactic, diagnostic or therapeutic purposes [28, 
29, 30, 31]. 
An alternative approach is the development of 
carriers with a functionalized surface, or on the basis 
of selectieve ligands focused on markers of excessive 
cell adhesion (MIKA), and on the basis of the 
antigen-lymphocyte function-related receptors low-
density lipoprotein. These approaches have led to the 
development of biologicaly to the data target. When 
inflammation of the endothelium actively allocated 
leukocytes regardless of the damage. Biomimetic 
carriers follow leukocyte tropism and selectively 
deliver a medicinal substance to the affected tissue. It 
was discovered that MICK focused on the 
Fe3O4SiO2 nanoparticles with multifunctional core-
shell, mainly absorbed by inflamed endothelial cells 
in comparison with untargeted nanoparticles 
liposomes MIKA, who was used in experiments on 
the model of atherosclerosis in mice, and 
demonstrated a pronounced therapeutic effect [32, 
33, 34, 35]. 
The strategy of treatment of cardiovascular 
diseases with preparations based on 
nanoparticles. 
For targeted delivery of pharmaceutical 
compositions in the endothelium are used in various 
types of biologicaly. For example, researchers have 
developed a carrier-based chloromethylketone and 
micelle-based nanoparticles with high affinity to 
blood clots. Chloromethylketone base was associated 
with the nanoparticles, perfluorocarbons, and 
micelles with anticoagulant. Both approaches showed 
a significant antithrombotic effect. Nanoparticles 
associated with indium having a surface 
functionalized with antibodies associated with 
receptors LHCP was used for visualization of 
atherosclerotic plaques in mice. Using a variety of 
approaches to the delivery of particles into the 
endothelium, it is possible to investigate 
nanoparticles in the circulatory system, to 
demonstrate translirovalis and track their 
accumulation in the inflamed tissue and excretion 
through the lymphatic system. Such studies provide 
important information that complements the study of 
their therapeutic efficacy [34, 36, 37, 38]. 
New ideas and opportunities for drug 
development 
The design of the surface of the media fragments 
that mimic the natural ligands, can provide selective 
targeting, precise delivery of therapeutic agents in 
diseased tissue. However, sequestration of 
nanoparticles in the mononuclear phagocytic system 
unable to adequately assess the biological barriers 
that hinders their clinical application. New 
biomimetic development is mainly based on two 
strategies:  
1) top-down approaches, i.e. development of
carrier-based microorganisms (such as bacteria or 
viruses), or cells (e.g. leukocytes, erythrocytes and 
platelets);  
2) bottom-up approaches such as the conjugation
of the nanoparticles surface with analogues of 
biologically active molecules that specifically bind to 
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the markers and selektine or coating of synthetic 
particles cell membranes. Additional approaches 
include polymers of lactic acid-glycolic acid (PLGA) 
– coated cells of platelets, which are mainly studied
on the model of coronary restenosis rats [33, 39, 
40, 41]. 
Other biomimetic nanoparticles based on the 
endogenous carriers such as LDL and HDL, was 
designed to include the nucleic material and the 
delivery of therapeutic and diagnostic molecules, 
low-density lipoproteins, which are also used as 
contrast agents in combination with gold 
nanoparticles. Methods of modification of 
endogenous proteins and the encapsulated delivery of 
lipophilic drugs continue to be studied and expanded, 
indicating their potential efficacy in selective 
targeting of drugs for the treatment of cardiovascular 
diseases [42, 43, 44]. 
In addition to the platforms and strategies 
referred to above, the group of Molinaro et al. 
recently published a new method that combines 
ascending and descending approaches to the 
Assembly of hybrid biomimetic nanovesicles. This 
combined approach represents an evolution of the 
coating process previously used for functionalization 
of the lipid vesicles. In this case, the membrane 
proteins are distinguished from infiltration of 
immune cells and restored biocompatible choline-
based phospholipids in liposomes and form 
nanovesicles called leucosome. Leukocytopenia 
properties were grafted into leucosomes through the 
integration of more than 300 membrane proteins in 
their status after the lipid bilayer. Among these 
properties, proteomic analysis revealed the presence 
of receptors that enhance adhesion to the activated 
vascular lakocom network, which revealed their 
autotolerance and the ability to evade the immune 
cleaning [45]. 
Despite the use of these platforms on the model 
of localized inflammation in mice, a description of 
the conservation of molecular pathways involved 
receptors and dynamic interactions between key cell 
types during the inflammatory process opens the 
possibility of using lakocom for the treatment of 
cardiovascular diseases where inflammation plays an 
important role in the activation of endothelial 
dysfunction. In sum, all of these biomedcode 
represent the next generation of nanomedical therapy, 
as they provide an alternative solution to evade 
mononuclear phagocytic system and transport 
through the endothelial wall of the vessel.  
Also worth mentioning is a new approach to 
drug delivery to the endothelium, through the 
creation of nanocapsules on the basis of high 
molecular weight polymers with a core in the form of 
medicinal substances. Was formulated transfer theory 
three-compartment pharmacokinetic model in a 
single model. Based on the obtained in our laboratory 
experimental data on endotheliopathy activity of 
some compounds was hypothesized that 
nanocapsules with a certain size range can penetrate 
into the bloodstream and not go beyond it, which will 
greatly reduce the necessary concentration of the 
medicinal substance for the treatment of 
cardiovascular diseases. Samples nanocapsule L-
arginine, losartan potassium and resveratrol based on 
xanthan gum and konjak Gunma Prefecture, obtained 
in the framework of this approach have dimensions 
of from 20 to 180 nm and greatly reduces the 
coefficient of endothelial dysfunction (CED) in an 
experiment with laboratory rats on the model of 
LNAME – induced endothelial dysfunction. These 
studies showed that nanocapsules reduce the CAD to 
a comparable level with the introduction of the 
original medicinal substances substances while the 
dosage of the studied drugs was 4 times less than the 
reference drug [46-57]. 
Conclusions 
A new platform for drug delivery can 
encapsulate a variety of molecules and deliver them 
selectively to areas of inflammation of the 
endothelium. For the affected endothelial drugs can 
be sent using the classical approaches based on 
antibodies and other ligands using new generation 
systems biomimetics. These systems are based on the 
unique biology of some of the phenotypes of the cells 
that have the ability to recognize and overcome the 
inflammation of the endothelial barrier. In particular, 
it is possible to develop a delivery system of 
nanoparticles that can be used to preserve some 
properties of immune cells such as macrophages, 
leukocytes and T-cells. Using exceptional ability of 
these cells to detect, recognize and penetrate 
inflammatory tissue, was created by alternative 
platforms that can selectively deliver therapeutic and 
diagnostic products in the field of interest in various 
pathological conditions associated with local 
inflammation of the vascular bed. Together these 
findings reveal three potential areas for further 
research:  
1) understanding of the pathophysiology of
cardiovascular diseases as a result of exploring ways 
of inflammation,  
2) development of therapeutic agents that
passively or actively delivered to the inflamed 
endothelium 
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3) overcoming the limitations of available drugs
with serious side effects and unwanted toxicity in 
healthy tissues.  
New developments in the field of production of 
nanoparticles, combined with an understanding of the 
inflammatory processes of the endothelium in the 
pathogenesis of cardiovascular diseases may soon to 
ensure the development of targeted delivery of novel 
therapeutic agents in the place of inflammation of the 
blood vessels, which will lead to greater efficiency 
and reduced systemic side effects. 
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